SunRock Biopharma y VHIO reciben financiación de €1.8 millones para el desarrollo de nuevos anticuerpos en el tratamiento del cáncer de ovario

by VHIO

Ambas entidades participan conjuntamente en el proyecto OVERCAD, cuyo objetivo es desarrollar una nueva estrategia terapéutica eficaz para el tratamiento de cáncer de ovario resistente, centrada en ...

Read more

ORYZON announces journal publication of final Phase IIa REIMAGINE results with vafidemstat in Psychiatry and Clinical Neurosciences

by Oryzon Genomics

The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (A...

Read more

MYC: from undruggable target to the first cancer clinical trials

by VHIO

The MYC oncogene is deregulated in approximately 70% of human cancers and is associated with aggressive disease and cancer drug resistance, making it one of the most sought-after targets in oncology. ...

Read more

Biomedicamento contra el síndrome inflamatorio derivado de infecciones pulmonares graves

by Peaches Biotech

Peaches Biotech está investigando con su ensayo piloto, en fase I-II, del PRS® CK STORM contra la tormenta de citoquinas que se da en una cantidad significativa de casos en personas afectadas por vi...

Read more

Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02

by Ysios Capital

ADCE-T02 is a potential first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate (ADC) targeting tissue factor, a validated ADC target overexpressed in multiple solid tumors

Read more

ORYZON reports financial results and corporate update for Q4 2024

by Oryzon Genomics

​Oryzon Genomics, S.A, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the fou...

Read more

Oryzon defines Phase III Trial endpoints for Agitation and Aggression in BPD with input from new Clinical Advisory Board

by Oryzon Genomics

Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD)

Read more

CONNECTA Therapeutics announces positive results from Phase I study of neurodevelopmental disorders drug candidate, CTH120

by Connecta Therapeutics

CTH120 is an investigational drug that modulates neuroplasticity, a property of the brain affected in many neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), Down...

Read more

Oryzon announces publication of study on Phelan-McDermid Syndrome (PMS) patients, a form of autism, paving the way for a novel personalized medicine approach with vafidemstat

by Oryzon Genomics

Study provides clinical scales and thresholds for patient selection in future clinical trials, based on aggressiveness, cognition, and behavioral traits

Read more

Nace Albor Biotech, la ‘spin-off’ de la USC que ejercerá de partner estratégico en el desarrollo de soluciones para combatir las patologías asociadas al síndrome metabólico

by Albor Biotech

La nueva compañía estará enfocada en las fases iniciales de desarrollo y validación preclínica de soluciones terapéuticas (CRO) dirigidas al área del metabolismo. Afrontará, según sus fundado...

Read more

Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett’s Syndrome (TREE study)

by Ysios Capital

TREE is a phase 2a clinical study assessing the safety and efficacy of lead candidate leriglitazone, a novel, brain-penetrant and selective PPAR gamma agonist, to treat patients with Rett syndrome.

Read more

New artificial intelligence method predicts drug-drug interactions with greater accuracy

by Universidad de Navarra

GENNIUS, developed by researchers from the University of Navarra and Stanford University, could revolutionize the process of finding new drugs.

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Telum Therapeutics Secures €18 Million...

by Telum Therapeutics

Telum Therapeutics, a biotechnology company leveraging proprietary met...

Photos Stream